Monograph: |
EDARAVONE (RADICUT) IS A NEUROPROTECTIVE AGENT USED FOR THE PURPOSE OF AIDING NEUROLOGICAL RECOVERY FOLLOWING ACUTE BRAIN ISCHEMIA AND SUBSEQUENT CEREBRAL INFARCTION. IT ACTS AS A POTENT ANTIOXIDANT AND STRONGLY SCAVENGES FREE RADICALS, PROTECTING AGAINST OXIDATIVE STRESS AND NEURONAL APOPTOSIS. IT HAS BEEN MARKETED SOLELY IN JAPAN BY MITSUBISHI PHARMA SINCE 2001.
EDARAVONE HAS BEEN SHOWN TO ATTENUATE METHAMPHETAMINE- AND 6-OHDA-INDUCED DOPAMINERGIC NEUROTOXICITY IN THE STRIATUM AND SUBSTANTIA NIGRA, AND DOES NOT AFFECT METHAMPHETAMINE-INDUCED DOPAMINE RELEASE OR HYPERTHERMIA. IT HAS ALSO BEEN DEMONSTRATED TO PROTECT AGAINST MPTP-MEDIATED DOPAMINERGIC NEUROTOXICITY TO THE SUBSTANTIA NIGRA, THOUGH NOTABLY NOT TO THE STRIATUM.
IT IS GIVEN BY INTRAVENOUS INFUSION IN A DOSE OF 30 MG TWICE DAILY, INFUSED OVER 30 MINUTES, BEGINNING WITHIN 24 HOURS OF STROKE ONSET AND CONTINUED FOR UP TO 14 DAYS.
|